Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | CALML3 | P27482 | 1/20 | 0.40 |
| ▸ | SDHA | P31040 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13298961 | 1.00 | CETP (0.44) | CETPKCNH2MAOAMAOBF10 | |
| SCHEMBL3327665 | 0.90 | MAOA (0.48) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL13298960 | 0.85 | MAOA (0.50) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL28752168 | 0.84 | CETP (0.36) | CETPKCNH2MAOAMAOBF10 | |
| SCHEMBL3328419 | 0.80 | MAOA (0.60) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL3325901 | 0.80 | MAOA (0.42) | CETPKCNH2MAOAMAOB | |
| SCHEMBL3326555 | 0.80 | MAOA (0.51) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL3328545 | 0.80 | MAOA (0.51) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL3328540 | 0.80 | MAOA (0.51) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL3326613 | 0.80 | MAOA (0.51) | MAOAMAOBF10LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-7396847-B2 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | CYP8B1, HRH2, CYP2W1 | CETP 4012/4885KCNH2 1898/4885MAOA 482/4885 |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | CYP8B1, CYP2W1, HRH2 | CETP 4206/4885KCNH2 2193/4885MAOA 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.